Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | EDNRB | P24530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20094731 | 0.91 | RIPK1 (0.84) | RIPK1RAB9ANPC1LMNASMN1; SMN2 | |
| SCHEMBL20094738 | 0.91 | RIPK1 (0.82) | RIPK1RAB9ANPC1LMNASMN1; SMN2 | |
| SCHEMBL20094737 | 0.89 | RIPK1 (0.81) | RIPK1RAB9ANPC1LMNASMN1; SMN2 | |
| SCHEMBL6565166 | 0.88 | RIPK1 (0.78) | RIPK1RAB9ANPC1LMNASMN1; SMN2 | |
| SCHEMBL6528998 | 0.75 | RIPK1 (0.59) | RIPK1RAB9ANPC1LMNASMN1; SMN2 | |
| SCHEMBL15575244 | 0.75 | RIPK1 (0.60) | RIPK1RAB9ANPC1LMNASMN1; SMN2 | |
| SCHEMBL27442244 | 0.74 | RIPK1 (0.59) | RIPK1RAB9ANPC1LMNASMN1; SMN2 | |
| SCHEMBL29375243 | 0.72 | KDM4E (0.60) | RIPK1LMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL27867197 | 0.72 | RIPK1 (0.56) | RIPK1RAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL27867198 | 0.72 | RIPK1 (0.56) | RIPK1RAB9ANPC1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277538-A1 | THERAPEUTICS FOR THE TREATMENT OF FSHD | UCL BUSINESS LTD (GB) | 2023-09-07 | — | — | US | claimed |
| US-11819492-B2 | Natural product derivatives for inhibiting cellular necroptosis, ferroptosis and oxytosis | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-11-21 | — | — | US | disclosed |
| US-11819492-B2 | Natural product derivatives for inhibiting cellular necroptosis, ferroptosis and oxytosis | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2023-11-21 | — | — | US | disclosed |
| US-20230277538-A1 | THERAPEUTICS FOR THE TREATMENT OF FSHD | UCL BUSINESS LTD (GB) | 2023-09-07 | — | — | US | disclosed |
| WO-2023122298-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20220096426-A1 | Natural Product Derivatives For Inhibiting Cellular Necroptosis, Ferroptosis And Oxytosis | SATT OUEST VALORISATION (FR) | 2022-03-31 | — | — | US | disclosed |
| US-11224586-B2 | Natural product derivatives for inhibiting cellular necroptosis, ferroptosis and oxytosis | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2022-01-18 | — | — | US | disclosed |
| US-20190262306-A1 | Natural Product Derivatives For Inhibiting Cellular Necroptosis, Ferroptosis And Oxytosis | SORBONNE UNIVERSITE (FR) | 2019-08-29 | — | — | US | disclosed |
| WO-2018073321-A1 | NATURAL PRODUCT DERIVATIVES FOR INHIBITING CELLULAR NECROPTOSIS, FERROPTOSIS AND OXYTOSIS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819492-B2 | Natural product derivatives for inhibiting cellular necroptosis, ferroptosis and oxytosis | AIFM2, AIFM1, CASP3 | RIPK1 18/4885RAB9A 3335/4885NPC1 510/4885 |
| US-11224586-B2 | Natural product derivatives for inhibiting cellular necroptosis, ferroptosis and oxytosis | AIFM2, AIFM1, CASP3 | RIPK1 17/4885RAB9A 3343/4885NPC1 513/4885 |
| US-20190262306-A1 | Natural Product Derivatives For Inhibiting Cellular Necroptosis, Ferroptosis And Oxytosis | AIFM2, AIFM1, CASP3 | RIPK1 17/4885RAB9A 3343/4885NPC1 513/4885 |
| US-20220096426-A1 | Natural Product Derivatives For Inhibiting Cellular Necroptosis, Ferroptosis And Oxytosis | AIFM2, AIFM1, CASP3 | RIPK1 18/4885RAB9A 3335/4885NPC1 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.